Sign Up Today and Learn More About Strella Biotechnology Stock
Invest in or calculate the value of your shares in Strella Biotechnology or other pre-IPO companies through EquityZen's platform.
Strella Biotechnology Stock (STBI)
Strella Biotechnology offers a biosensing platform that predicts the ripeness of fruit which reduces waste and improves product quality.
About Strella Biotechnology Stock
Founded
2018
Headquarters
Philadelphia, PA, US
Industries
Messaging and Telecommunications, Sports, Content and Publishing
Strella Biotechnology Press Mentions
Stay in the know about the latest news on Strella Biotechnology
Ethylene receptor biosensor
patents • Apr 02, 2025
The Gross Law Firm Notifies Sana Biotechnology, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - SANA
marketscreener • Mar 31, 2025
SANA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Sana Biotechnology, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
tradingview • Mar 30, 2025
Tobiko Data Announces General Availability of Enterprise-Grade Solution
businesswire • Mar 26, 2025
Ethylene Receptor Biosensor
patents • Apr 13, 2024
Strella Biotechnology Management
Leadership team at Strella Biotechnology
COO & Co-Founder
Jacob Jordan
CEO & Co-Founder
Katherine Sizov
Join now and verify your accreditation status to gain access to:
- Strella Biotechnology Current Valuation
- Strella Biotechnology Stock Price
- Strella Biotechnology Management
- Available deals in Strella Biotechnology and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Strella Biotechnology Cap Table and Funding History by Share Class and Liquidity Preferences
- Strella Biotechnology Revenue and Financials
- Strella Biotechnology Highlights
- Strella Biotechnology Business Model
- Strella Biotechnology Risk Factors
- Strella Biotechnology Research Report from SACRA Research
Trading Strella Biotechnology Stock
How to invest in Strella Biotechnology stock?
Accredited investors can buy pre-IPO stock in companies like Strella Biotechnology through EquityZen funds. These investments are made available by existing Strella Biotechnology shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Strella Biotechnology stock?
Shareholders can sell their Strella Biotechnology stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
